EP Patent

EP0237952A1 — Process for the preparation of 5H-Dibenzo-(b, f)-azepine

Assigned to Orion Oyj · Expires 1987-09-23 · 39y expired

What this patent protects

The invention refers to a new process for the preparation of a valuable intermediate, 5H-Dibenzo-(b, f)-azepine or iminostilbene by catalytic dehydrogenation of lO,ll-­Dihydro-5H-dibenzo-(b, f)-azepine or iminodibenzyl in liquid phase in one step in the presence of hydrogen accep…

USPTO Abstract

The invention refers to a new process for the preparation of a valuable intermediate, 5H-Dibenzo-(b, f)-azepine or iminostilbene by catalytic dehydrogenation of lO,ll-­Dihydro-5H-dibenzo-(b, f)-azepine or iminodibenzyl in liquid phase in one step in the presence of hydrogen acceptor. Dimethylaniline or diphenylether may be used as a solvent and as catalyst, nobel metal catalysts, such as platinum or palladium on activated carbon or metaloxide catalysts, such as Fe₂O₃ may be used in the dehydrogena­tion reaction. Nitrotoluenes, dimethylmaleate or tetra­chlorobenzochinone may be used as hydrogen acceptors. The yield of iminostilbene is 77-82°C of the theoretical.

Drugs covered by this patent

Patent Metadata

Patent number
EP0237952A1
Jurisdiction
EP
Classification
—
Expires
1987-09-23
Drug substance claim
No
Drug product claim
No
Assignee
Orion Oyj
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.